v3.24.2.u1
NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 05, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue Recognized $ 659,825 $ 318,754 $ 1,154,158 $ 638,044  
Roche | Roche Collaboration and License Agreement          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 922,000   922,000    
Revenue Recognized 12,797 0 84,948 0  
Roche | Roche License Obligation | Roche Collaboration and License Agreement          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 375,000   375,000    
Revenue Recognized 0 0 65,000 0  
Roche | Roche Development Services Obligation | Roche Collaboration and License Agreement          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 545,000   545,000    
Revenue Recognized 12,797 0 19,948 0  
Roche | Roche Technology Transfer Obligation | Roche Collaboration and License Agreement          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 2,000   2,000    
Revenue Recognized 0 0 0 0  
Regeneron Pharmaceuticals | Global Strategic Collaboration          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 169,760   169,760   $ 329,686
Revenue Recognized 12,800 (13,900) 29,200 (1,000)  
Regeneron Pharmaceuticals | Research Services Obligation | Global Strategic Collaboration          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 102,969   102,969   75,469
Revenue Recognized 4,000 (17,000) 18,700 (6,300)  
Regeneron Pharmaceuticals | C5 License Obligation | Global Strategic Collaboration          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transactional price remaining performance obligation 60,484   60,484   $ 56,390
Revenue Recognized $ 8,800 $ 3,100 $ 10,500 $ 5,300